Abstract 5779
Background
Drug resistance is an important clinical problem affecting the prognosis of colorectal cancer patients with initially unresectable liver metastases. The role of 5-hydroxymethylcytosine (5-hmC) in this process is still unknown.
Methods
A single-center study was conducted to enroll colorectal cancer patients with initially unresectable liver metastases at Zhongshan Hospital, Shanghai. The 5-hmC levels of each gene locus in circulating-free DNA (cfDNA) were detected using a highly sensitive sequencing method before the patient received any conversion therapy. Eight weeks after conversion therapy, patients with disease progression according to RECIST 1.1 were defined as drug-resistant group, while patients with complete response, partial response and stable disease were defined as the drug-effective group. By using the gene loci with the most significant difference of 5-hmC level, a predictive model (Logistic regression) was established based on machine-learning method. Then, we validated the model.
Results
From June 2018 to January 2019, 35 patients were enrolled, including 20 patients in drug-effective group and 15 in drug-resistant group. The predictive model was established using the first 100 significantly different gene loci and 10 loci were included in the model. The internal validation results suggested that the sensitivity (predictive accuracy for drug-resistant patients) and specificity (predictive accuracy for drug-effective patients) were 86.7% and 95.0%, respectively, and the area under the ROC curve is 0.990.
Conclusions
Our study screened the gene loci with different 5-hmC level between drug-effective and drug-resistant colorectal cancer patients with initial unresectable liver metastases. Then we established a predictive model for the efficacy of conversion therapy, although this model is still being improved and validated by enrolling more subjects.
Clinical trial identification
NCT03679039 09/18/2018.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2786 - Development of a living organoid biobank derived from colorectal cancer patients: towards personalized medicine
Presenter: Federica Papaccio
Session: Poster Display session 2
Resources:
Abstract
3351 - Microsatellite Instability Detection in Colorectal Cancer: 44-Center Comparison between the Idylla MSI Assay and Routine Molecular and Immunohistochemistry Tests on Formalin-Fixed Paraffin-Embedded Tissue
Presenter: Xavier Matias-guiu
Session: Poster Display session 2
Resources:
Abstract
4901 - Expression profile of EPHB3 and its prognostic significance in colorectal cancer progression (Running head: Prognostic value of EPHB3 in colorectal cancers)
Presenter: Bogun Jang
Session: Poster Display session 2
Resources:
Abstract
5030 - A pan-ErbB family inhibitor, AF8c, promotes apoptosis by DR5/Nrf2 activation via ROS in colorectal cancer cells
Presenter: Soyeon Jeong
Session: Poster Display session 2
Resources:
Abstract
5053 - Frequent BRAF, GNAS and SMAD4 mutations identified in Colorectal Mucinous Carcinomas
Presenter: Sun Mi Lee
Session: Poster Display session 2
Resources:
Abstract
5220 - Impact of CCL4 knockout using CRISPR Cas-9 technology on colorectal tumor progression
Presenter: Roba Barakat
Session: Poster Display session 2
Resources:
Abstract
5330 - Independent clinical validation of a gene expression profile to predict benefit of 5-FU in metastatic colorectal cancer
Presenter: Ida Buhl
Session: Poster Display session 2
Resources:
Abstract
5515 - WRN mutated Colorectal Cancer (CRC) is characterized by a distinct molecular and immunological profile
Presenter: Andreas Seeber
Session: Poster Display session 2
Resources:
Abstract
5716 - Mutation analysis of B2M gene in colorectal cancer patients with microsatellite instability
Presenter: Ivana Kašubová
Session: Poster Display session 2
Resources:
Abstract
870 - Selective Wnt/β-catenin small-molecule inhibitor CWP232228 impairs tumor growth of colon cancer
Presenter: Jin Young Kim
Session: Poster Display session 2
Resources:
Abstract